{"id":56065,"date":"2026-02-02T22:11:53","date_gmt":"2026-02-02T14:11:53","guid":{"rendered":"https:\/\/flcube.com\/?p=56065"},"modified":"2026-02-02T22:11:54","modified_gmt":"2026-02-02T14:11:54","slug":"sciwinds-ecnoglutide-wins-nmpa-nod-as-first-camp-biased-glp-1-agonist","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56065","title":{"rendered":"Sciwind&#8217;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist"},"content":{"rendered":"\n<p><strong>Sciwind Biosciences Co., Ltd.<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>ecnoglutide<\/strong> for glycemic control in adult patients with <strong>type\u202f2 diabetes<\/strong>, making it the <strong>world&#8217;s first marketed cAMP\u2011biased GLP\u20111 receptor agonist<\/strong>. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sciwind Biosciences Co., Ltd. (China)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Ecnoglutide<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Glycemic control in adult type\u202f2 diabetes patients<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>World&#8217;s first cAMP\u2011biased GLP\u20111 receptor agonist<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Preferentially activates cAMP signaling, minimizes \u03b2\u2011arrestin recruitment<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Phase\u202fIII studies EECOH\u20111 (monotherapy) and EECOH\u20112 (metformin combination)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Signaling Bias:<\/strong> Unlike traditional GLP\u20111 receptor agonists, ecnoglutide preferentially activates the <strong>cAMP pathway<\/strong> while limiting <strong>\u03b2\u2011arrestin recruitment<\/strong><\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Reduced \u03b2\u2011arrestin signaling limits receptor desensitization and downregulation, allowing more receptors to remain on the cell surface for sustained therapeutic signaling<\/li>\n\n\n\n<li><strong>Enhanced Efficacy:<\/strong> cAMP bias helps improve glycemic control, weight reduction, and metabolic benefits compared to non\u2011biased agonists<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-clinical-data\">Phase III Clinical Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>EECOH\u20111<\/strong><\/td><td>Monotherapy in Chinese T2D patients<\/td><td>Sustained glycemic control, weight loss, metabolic improvement over 52 weeks<\/td><\/tr><tr><td><strong>EECOH\u20112<\/strong><\/td><td>Combination with metformin<\/td><td>Significant A1C reduction, favorable safety profile maintained<\/td><\/tr><tr><td><strong>Common Results<\/strong><\/td><td>Both studies<\/td><td>Sustained efficacy over 52 weeks, overall favorable safety and tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GLP\u20111 Market:<\/strong> Valued at <strong>\u00a550\u202fbillion<\/strong> : (~US$7\u202fbillion) in 2025, growing at <strong>25% CAGR<\/strong> driven by obesity and diabetes demand<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Ecnoglutide enters market dominated by <strong>semaglutide (Novo Nordisk)<\/strong> and <strong>tirzepatide (Lilly)<\/strong>; cAMP\u2011biased mechanism offers differentiation<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a53\u20135\u202fbillion<\/strong> (US$420\u2013700\u202fmillion) peak annual sales by 2030, assuming 5\u20138% market share in China\u2019s GLP\u20111 segment<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions Sciwind as an innovator in next\u2011generation GLP\u20111 therapies with global franchise potential<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Commercial launch expected <strong>Q2\u202f2026<\/strong>; potential ex\u2011China partnership discussions underway<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for ecnoglutide. Actual results may differ due to competitive dynamics, market adoption rates, and pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56071,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4361,15,822],"class_list":["post-56065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hot-targets","tag-product-approvals","tag-sciwind-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sciwind&#039;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world&#039;s first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56065\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sciwind&#039;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist\" \/>\n<meta property=\"og:description\" content=\"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world&#039;s first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56065\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T14:11:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T14:11:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sciwind&#8217;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist\",\"datePublished\":\"2026-02-02T14:11:53+00:00\",\"dateModified\":\"2026-02-02T14:11:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0211-1.webp\",\"keywords\":[\"Hot targets\",\"Product approvals\",\"Sciwind Biosciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56065#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56065\",\"name\":\"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0211-1.webp\",\"datePublished\":\"2026-02-02T14:11:53+00:00\",\"dateModified\":\"2026-02-02T14:11:54+00:00\",\"description\":\"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world's first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56065\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0211-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0211-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56065#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sciwind&#8217;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist - Insight, China&#039;s Pharmaceutical Industry","description":"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world's first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56065","og_locale":"en_US","og_type":"article","og_title":"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist","og_description":"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world's first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.","og_url":"https:\/\/flcube.com\/?p=56065","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T14:11:53+00:00","article_modified_time":"2026-02-02T14:11:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56065#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56065"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sciwind&#8217;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist","datePublished":"2026-02-02T14:11:53+00:00","dateModified":"2026-02-02T14:11:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56065"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","keywords":["Hot targets","Product approvals","Sciwind Biosciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56065#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56065","url":"https:\/\/flcube.com\/?p=56065","name":"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56065#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","datePublished":"2026-02-02T14:11:53+00:00","dateModified":"2026-02-02T14:11:54+00:00","description":"Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide for glycemic control in adult patients with type\u202f2 diabetes, making it the world's first marketed cAMP\u2011biased GLP\u20111 receptor agonist. The approval marks a significant innovation in the GLP\u20111 class, which is dominated by non\u2011biased agonists.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56065#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56065"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56065#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","width":1080,"height":608,"caption":"Sciwind's Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56065#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sciwind&#8217;s Ecnoglutide Wins NMPA Nod as First cAMP\u2011Biased GLP\u20111 Agonist"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0211-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56065"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56065\/revisions"}],"predecessor-version":[{"id":56072,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56065\/revisions\/56072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56071"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}